Morgan Stanley Remains Bullish on Ascendis Pharma (ASND)

Ascendis Pharma A/S (NASDAQ:ASND) is one of the top high growth international stocks to buy right now. On September 8, Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Ascendis Pharma A/S (NASDAQ:ASND) and set a price target of $250.00.

Is Ascendis Pharma A/S (ASND) the Best Growth Stock to Buy According to Billionaires?

Ascendis Pharma A/S (NASDAQ:ASND) reported its fiscal Q2 2025 results on August 7, announcing €103.0 million in revenue for YORVIPATH and €50.7 million for SKYTROFA.

Jan Mikkelsen, Ascendis Pharma’s (NASDAQ:ASND) President and Chief Executive Officer, stated that the company is on the cusp of considerably transforming its financial profile and bringing its third high-value medicine to patients with the “robust global uptake of YORVIPATH and with TransCon CNP under U.S. FDA priority review.”

Headquartered in Hellerup, Denmark, Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company that develops drug candidates. It specializes in its TransCon technologies for the development of new therapies addressing unmet medical needs.

While we acknowledge the potential of ASND to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ASND and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.